SEC filing record
Primary Source · SEC.gov

Curavit Clinical Research Corp

2022 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2024-09-055 events: 2 sold increased, 2 offering upsized, 1 investors increasedLast filing 2024-09-05

Raised

$11M

Investors

30

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Curavit Clinical Research Corp is a Delaware corporation that first filed a Form D on October 13, 2022 and most recently amended it on September 5, 2024 in the Other Health Care industry group. The offering claims Rule 506(b) and covers equity. Curavit Clinical Research Corp reported $11,426,701 sold from 30 investors of a $11,646,575 total offering as of the Form D filed September 5, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 18 Larch Lane, Scarsdale, NY 10583.

Critical Disclosures

What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.

Reporting lapsed · Form D · last filing September 5, 2024

Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.

Timeline
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001947723
Entity NameCuravit Clinical Research Corp
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address18 Larch Lane, Scarsdale, NY 10583
Phone(917) 885-0024
Industry / Fund TypeOther Health Care
Securities TypeEquity
First Sale DateSeptember 28, 2022
Filing DateSeptember 5, 2024
Accession Number0001947723-24-000002
Total Offering Amount$11,646,575
Total Amount Sold$11,426,701
Amount Remaining$219,874
Total Investors30
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationIntended to last more than one year
Sales Commissions$0
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)NY
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

5

latest Sep 5, 2024

Critical / warning

0 / 0

0 watch · 5 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

dark

Latest event Sold increase · Sep 5, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 5 filing events with values and deltas, latest 2024-09-05, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Joel Morse

Executive Officer, Director · Scarsdale, NY

David Hanaman

Director · Scarsdale, NY

Nathanael Lentz

Director · Scarsdale, NY

Rich Lester

Director · Scarsdale, NY

Jackie Kent

Director · Scarsdale, NY

Questions About Curavit Clinical Research Corp

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Curavit Clinical Research Corp?

Curavit Clinical Research Corp is a Delaware corporation that filed a Form D with the SEC on September 5, 2024 in the Other Health Care industry group. The filing claims Rule 506(b) for an offering of equity.

Is Curavit Clinical Research Corp legit?

AltStreet does not rate legitimacy; it reports the public record. Curavit Clinical Research Corp filed a Form D with the SEC on September 5, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $11,426,701 sold to 30 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Curavit Clinical Research Corp registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Curavit Clinical Research Corp claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Curavit Clinical Research Corp raised?

Curavit Clinical Research Corp reported $11,426,701 sold from 30 investors of a $11,646,575 total offering as of the Form D filed September 5, 2024.

Who can invest in Curavit Clinical Research Corp?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Curavit Clinical Research Corp?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Curavit Clinical Research Corp and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Curavit Clinical Research Corp?

The Form D lists 5 related persons: Joel Morse, executive officer, director; David Hanaman, director; Nathanael Lentz, director; Rich Lester, director; Jackie Kent, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Curavit Clinical Research Corp located?

The issuer's address on its SEC filings is 18 Larch Lane, Scarsdale, NY 10583. Its phone number of record is 917-885-0024. It is organized under the laws of Delaware.

How long is the Curavit Clinical Research Corp offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

What is Curavit Clinical Research Corp's revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.